|Year : 2020 | Volume
| Issue : 2 | Page : 172-176
Biorisk assessment for infrastructure & biosafety requirements for the laboratories providing coronavirus SARS-CoV-2/(COVID-19) diagnosis
Devendra T Mourya1, Gajanan Sapkal2, Pragya D Yadav3, Sujeet Kumar M Belani2, Anita Shete3, Nivedita Gupta4
1 ICMR-National Institute of Virology, Pune, Maharashtra, India
2 Diagnostic Virology Group, ICMR-National Institute of Virology, Pune, Maharashtra, India
3 Maximum Containment Laboratory, ICMR-National Institute of Virology, Pune, Maharashtra, India
4 Division of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi, India
|Date of Web Publication||28-Apr-2020|
Dr Devendra T Mourya
ICMR-National Institute of Virology, Pune 411 021, Maharashtra
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Novel coronavirus infection [coronavirus disease 2019 (COVID-19)] has spread to more than 203 countries of various regions including Africa, America, Europe, South East Asia and Western Pacific. The WHO had declared COVID-19 as the global public health emergency and subsequently as pandemic because of its worldwide spread. It is now one of the top-priority pathogens to be dealt with, because of high transmissibility, severe illness and associated mortality, wide geographical spread, lack of control measures with knowledge gaps in veterinary and human epidemiology, immunity and pathogenesis. The quick detection of cases and isolating them has become critical to contain it. To meet the increasing demand of the diagnostic services, it is necessary to enhance and expand laboratory capabilities since existing laboratories cannot meet the emerging demand. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a BSL-2 (Biosafety Level 2) agent and needs to be handled in biosafety cabinet using standard precautions. This review highlights minimum requirements for the diagnostic laboratories opting testing of material for the diagnosis of COVID-19 and associated biorisk to the individuals and to the community.
Keywords: Biorisk - biosafety - diagnosis - infrastructure - laboratories - novel coronavirus
|How to cite this article:|
Mourya DT, Sapkal G, Yadav PD, M Belani SK, Shete A, Gupta N. Biorisk assessment for infrastructure & biosafety requirements for the laboratories providing coronavirus SARS-CoV-2/(COVID-19) diagnosis. Indian J Med Res 2020;151:172-6
|How to cite this URL:|
Mourya DT, Sapkal G, Yadav PD, M Belani SK, Shete A, Gupta N. Biorisk assessment for infrastructure & biosafety requirements for the laboratories providing coronavirus SARS-CoV-2/(COVID-19) diagnosis. Indian J Med Res [serial online] 2020 [cited 2021 May 14];151:172-6. Available from: https://www.ijmr.org.in/text.asp?2020/151/2/172/281912
| Introduction|| |
Coronaviruses are enveloped viruses with non-segmented positive-sense RNA, widely distributed in humans and animals,. Initially, infections caused by several human coronaviruses (HCoVs) were only mild and hence were considered as neglected pathogens. After the emergence of highly pathogenic severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) (2002 and 2003) and Middle East respiratory syndrome coronavirus (MERS-CoV, 2012), it has become obvious that coronaviruses can cross the species barrier and cause life-challenging infections in human, thus needing greater attention than the initial HCoVs.
Recently, another pathogenic HCoV was identified in Wuhan, People's Republic of China, which was initially named as 2019 novel coronavirus (2019-nCoV). But later, it has been named as SARS-CoV-2 by the International Committee on Taxonomy of Viruses (ICTV). This virus causes coronavirus disease 2019 (COVID-19). The clinical presentation of infection ranges from asymptomatic to very severe pneumonia with acute respiratory distress syndrome, septic shock and multi-organ failure resulting in death. As of March 2020, SARS-CoV-2 has spread to more than 203 countries of various regions including Africa, America, Europe, South East Asia and Western Pacific alarming public health authorities around the world.
Since, the first case reported on December 31, 2019, the WHO has been notified with more than 100,000 confirmed cases including 3,380 deaths globally as on March 6, 2020, of whom 90 per cent (3,045) were from China itself, while the remaining 10 per cent (335) were from other countries. The SARS-CoV-2 is now one of the top-priority pathogens to be dealt with, because of high fatality rate in severe cases, spread in a wide geographical area, lack of control measures and knowledge gaps in its epidemiology, immunity and pathogenesis. Currently, there are no licensed vaccines or therapies specific to COVID-19. Hence, the WHO has initially declared COVID-19 as the global public health emergency and subsequently as pandemic.
Because of the rapid spread of this virus, it has become necessary to enhance laboratory capabilities to provide immediate diagnostic assistance as the load of samples from suspected patients is increasing on a daily basis and existing laboratories cannot meet the demands. The objective of this review is to highlight various requirements for the diagnostic laboratories involved in the testing of SARS-CoV-2 and also describe measures to mitigate the risk factors involved in laboratories that are providing molecular diagnosis, so that more laboratories become available for providing quick diagnosis under all safety precautions.
| Sample of choice|| |
Coronaviruses are mainly responsible for respiratory tract infections resulting in symptoms such as common flu. Choice of sample for detection will be respiratory samples including clinical material from the upper and lower respiratory tracts depending on the symptoms and condition of the patient,. For SARS-CoV-2, shedding patterns are not well understood and further investigations are required to understand the timing, compartmentalization and magnitude of virus shedding. However, the virus may be detectable in other specimens including blood and urine as in cases of SARS-CoV-1 and MERS-CoV,,. The mean incubation period for SARS-CoV-2 is 5.2 days; however, it may vary widely depending on severity of illness.
| Specimen collection|| |
Only trained staff should be allowed for appropriate specimen collection, storage, packaging and transport, ensuring that adequate standard operating procedures in consonance with the national or the WHO guidelines are in use, and all specimens should be treated as potentially infectious.
| Diagnosis|| |
Suspected cases should be tested for the virus with nucleic acid amplification tests, such as real-time reverse transcription - polymerase chain reaction (RT-PCR) with confirmation by nucleic acid sequencing when needed. Viral RNA extraction should be done in a biosafety cabinet in a BSL-2 or equivalent facility, which will be used further for amplification of genes targeted including nucleocapsid (N), spike (S), envelope (E), and RNA-dependent RNA polymerase (RdRp). Serological tests are still under development, and once these become available, field surveys will aid in better understanding of the outbreak, implementation of control measures and also understanding cross-reactivity with other viruses.
| Infrastructure needed|| |
Suspected samples should be handled at initial phase in a biosafety cabinet by well-trained staff with respect to standard BSL-2 facility. National guidelines on laboratory biosafety should be followed in all circumstances. At present, very limited information is available on the risk posed by COVID-19, therefore, all procedures should be undertaken based on risk assessment.
Specimen handling for molecular testing of COVID-19 would require BSL-2 or equivalent facilities. These facilities include separate hand and eye wash sinks, and these also need to have automatic door locking systems. The BSL-2 laboratories should have access to facility of decontamination, including an autoclave.
It is recommended that good microbiological laboratory practices and universal precautions must be followed in all laboratories where primary specimens (such as sputum, throat swab, nasopharyngeal swab, oropharyngeal swab, and stool) that may contain SARS-CoV-2 virus, are handled. While working with suspected patient's samples, laboratory personnel should be supervised by staff competent in handling infectious agents and related standard procedures. The list of basic laboratory equipment and reagents required for providing laboratory diagnosis for COVID-19 is provided in [Table 1].
|Table 1: List of laboratory equipments and reagents required for laboratory diagnosis of coronavirus disease 2019 (COVID-19) and personal protective equipment (PPE) for carrying out COVID-19 molecular test|
Click here to view
| Biosafety measures|| |
In most cases, SARS-CoV-2 is transmitted from human to human through inhalation or deposition on mucosal surfaces of large respiratory droplets. Other routes identified are contact with contaminated fomites and inhalation of aerosol, generated during handling of large volumes, etc. For the laboratories involved in the diagnosis of COVID-19, it is necessary that staff should be well trained in the implementation of appropriate biosafety measures. The rational, correct and consistent use of available personal protective equipment (PPE) and appropriate hand hygiene help to reduce the spread of the pathogens. Though PPE is considered as a primary prevention strategy, it should not be completely relied upon for complete prevention for virus transmission. The effectiveness of PPE depends upon proper handling of PPEs by trained staff, hand hygiene practices and human factor,,,. Immunization policy for influenza would also help in giving protection to laboratory workers and reduce the suspicion of the staff to be getting infection in such emergency situation. Basic biosafety requirements for the laboratories that include important features of procedures and processes to be followed during processing the samples for COVID-19 laboratory diagnosis are provided in [Table 2].
|Table 2: Basic biosafety requirements for the laboratories (some important features of procedures and processes to be followed during processing samples for coronavirus disease 2019 laboratory diagnosis)|
Click here to view
Biorisk assessment carried out for individual laboratory personnel and to the community with regard to providing molecular diagnosis for COVID-19 is provided in the [Figure 1] This biorisk assessment will also provide guidance for the future laboratories that are opting to provide laboratory diagnosis for this infection.
|Figure 1: Biorisk assessment for individual laboratory personnel and community with regard to providing molecular diagnosis for coronavirus disease 2019. Likelihood of secondary transmission to human is on moderate risk, in case laboratory personnel get infected while handling infected material.|
Click here to view
Financial support & sponsorship: None.
Conflicts of Interest: None.
| References|| |
Richman DD, Whitley RJ, Hayden FG. Clinical virology
. New York: John Wiley & Sons; 2016.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al
. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet
Fauci AS, Lane HC, Redfield RR. Covid-19 - Navigating the Uncharted. N Engl J Med
Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, et al
. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses
Paules CI, Marston HD, Fauci AS. Coronavirus Infections- more than just the common cold. JAMA
Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al
. The species severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol
European Centre for Disease Prevention and Control. Infection prevention and control for COVID-19 in healthcare settings - March 2020
. Stockholm: ECDC; 2020.
Centers for Disease Control and Prevention. COVID-19 Situation Summary
. CDC; 2020. Available from:
, accessed on March 12, 2020.
Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, et al
. Management of corona virus disease-19 (COVID-19): The Zhejiang experience. Zhejiang Da Xue Xue Bao Yi Xue Ban
Zhang Y, Chen C, Zhu S, Shu C, Wang D, Song J, et al
. Isolation of 2019-nCoV from a stool specimen of a laboratory-confirmed case of the coronavirus disease 2019 (COVID-19). CCDC Weekly
Shi X, Gong E, Gao D, Zhang B, Zheng J, Gao Z, et al
. Severe acute respiratory syndrome associated coronavirus is detected in intestinal tissues of fatal cases. Am J Gastroenterol
Zhou J, Li C, Zhao G, Chu H, Wang D, Yan HHN, et al
. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Sci Adv Am Assoc Adv Sci
Ding Y, He L, Zhang Q, Huang Z, Che X, Hou J, et al
. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al
. Early transmission dynamics in Wuhan, China of novel coronavirus-infected pneumonia. N Engl J Med
World Health Organization. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: Interim guidance
. WHO; 2020. Available from: https://apps.who.int/iris/handle/10665/331329
, accessed on March 12, 2020.
Mourya DT, Yadav PD, Majumdar TD, Chauhan DS, Katoch VM. Establishment of Biosafety Level-3 (BSL-3) laboratory: Important criteria to consider while designing, constructing, commissioning & operating the facility in Indian setting. Indian J Med Res
Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology
[Table 1], [Table 2]
|This article has been cited by|
||Implementation of Bio-Risk Management System in a National Clinical and Medical Referral Centre Laboratories
| ||Fatma Lestari,Abdul Kadir,Thariq Miswary,Cynthia Febrina Maharani,Anom Bowolaksono,Debby Paramitasari |
| ||International Journal of Environmental Research and Public Health. 2021; 18(5): 2308 |
|[Pubmed] | [DOI]|
||Strengthening of Molecular Diagnosis of SARS-CoV-2 / COVID-19 with a Special Focus on India
| ||Ragini Bhatia,Rajesh Chaudhary,Sandip Kumar Khurana,Ruchi Tiwari,Kuldeep Dhama,Vivek Kumar Gupta,Raj Kumar Singh,Senthilkumar Natesan |
| ||Journal of Pure and Applied Microbiology. 2020; 14(suppl 1): 789 |
|[Pubmed] | [DOI]|
||Ramping up of SARS CoV-2 testing for the diagnosis of COVID-19 to better manage the next phase of pandemic and reduce the mortality in India
| ||Senthilkumar Natesan,Ragini Bhatia,Aarthi Sundararajan,Kuldeep Dhama,Yashpal S. Malik,Kranti Vora |
| ||VirusDisease. 2020; |
|[Pubmed] | [DOI]|